NASDAQ:MYGN - Myriad Genetics Stock Price, Forecast & News

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Monday, November, 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.26 by $0.18. The firm had revenue of $186.30 million for the quarter, compared to the consensus estimate of $202.34 million. Myriad Genetics had a positive return on equity of 6.48% and a negative net margin of 1.83%. The company's revenue was down 7.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.43 EPS. View Myriad Genetics' Earnings History.

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Myriad Genetics.

Myriad Genetics issued an update on its FY20 earnings guidance on Monday, November, 4th. The company provided earnings per share (EPS) guidance of $1.00-1.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.78. The company issued revenue guidance of $800-810 million, compared to the consensus revenue estimate of $872.74 million.

7 equities research analysts have issued 12-month price objectives for Myriad Genetics' shares. Their forecasts range from $18.00 to $36.00. On average, they expect Myriad Genetics' stock price to reach $27.66 in the next year. This suggests that the stock has a possible downside of 2.7%. View Analyst Price Targets for Myriad Genetics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.

Press coverage about MYGN stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myriad Genetics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Myriad Genetics.

Myriad Genetics saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 13,670,000 shares, an increase of 32.1% from the December 31st total of 10,350,000 shares. Based on an average daily trading volume, of 991,300 shares, the short-interest ratio is currently 13.8 days. Approximately 18.9% of the company's stock are short sold. View Myriad Genetics' Current Options Chain.

Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Alibaba Group (BABA), Incyte (INCY), Kratos Defense & Security Solutions (KTOS), STMicroelectronics (STM) and Gilead Sciences (GILD).

Myriad Genetics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CWM LLC (0.82%), California Public Employees Retirement System (0.24%), New York State Teachers Retirement System (0.10%), State of Alaska Department of Revenue (0.08%), Taylor Frigon Capital Management LLC (0.07%) and Arizona State Retirement System (0.07%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

MYGN stock was sold by a variety of institutional investors in the last quarter, including Arizona State Retirement System, Ingalls & Snyder LLC, Eqis Capital Management Inc., Louisiana State Employees Retirement System, Virginia Retirement Systems ET AL and State of Alaska Department of Revenue. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Ralph L Mcdade and Richard Bryan Riggsbee. View Insider Buying and Selling for Myriad Genetics.

MYGN stock was purchased by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, CWM LLC, Traverso Chambers Private Wealth Management LLC, California Public Employees Retirement System, Exchange Traded Concepts LLC, 6 Meridian, Taylor Frigon Capital Management LLC and Nisa Investment Advisors LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYGN stock can currently be purchased for approximately $28.43.

Myriad Genetics has a market capitalization of $2.11 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.View Additional Information About Myriad Genetics.

The official website for Myriad Genetics is http://www.myriad.com/.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]